Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Monopar Therapeutics changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 6 | 18 | +12 |
| Shares | 15.7K | 2.58M | +2.56M (+16,314.9%) |
| Value | $105.9K | $57.1M | +$57.0M (+53,860.7%) |
New holders (12)
Institutions that held Monopar Therapeutics at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Janus Henderson Group PLC | 1,046,899 | $23.4M | 0.01% |
| Adage Capital Partners GP, L.L.C. | 599,195 | $13.2M | 0.02% |
| Ra Capital Management, L.P. | 511,207 | $11.2M | 0.15% |
| Point72 Asset Management, L.P. | 167,892 | $3.69M | 0.01% |
| ADAR1 Capital Management, LLC | 130,037 | $2.86M | 0.59% |
| Vanguard Group Inc | 56,509 | $1.24M | 0.00% |
| BlackRock, Inc. | 8,101 | $178.2K | 0.00% |
| Ikarian Capital, LLC | 5,908 | $130.0K | 0.04% |
| Morgan Stanley | 3,801 | $83.6K | 0.00% |
| JPMorgan Chase & Co | 2,037 | $44.8K | 0.00% |
| Tower Research Capital LLC (TRC) | 696 | $15.3K | 0.00% |
| SBI Securities Co., Ltd. | 100 | $2.20K | 0.00% |
Sold out (0)
Institutions that held Monopar Therapeutics at the end of Q3 2024 and filed for Q4 2024 without it.
None.